Stock Track | Phathom Pharmaceuticals Soars 5.79% Pre-market on Strong Q3 Results and Analyst Upgrade

Stock Track

Oct 31

Phathom Pharmaceuticals (PHAT) stock is surging 5.79% in pre-market trading on Friday, following the release of its third-quarter 2025 earnings report and a positive analyst update. The pharmaceutical company's shares are gaining momentum as investors react to the latest financial results and revised market outlook.

The company's Q3 earnings release, while details are limited, suggests strong growth for Phathom Pharmaceuticals in the third quarter of 2025. This positive performance has caught the attention of Wall Street analysts, with H.C. Wainwright raising its target price for PHAT stock from $20 to $26, signaling increased confidence in the company's future prospects.

Adding to the bullish sentiment, HC Wainwright & Co. has maintained its Buy rating on Phathom Pharmaceuticals. This combination of strong quarterly results and analyst optimism appears to be driving the significant pre-market rally, as investors position themselves ahead of the regular trading session in anticipation of potential further gains.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1159604203"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1159604203\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1159604203?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 21:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1159604203","market":"us","top_or_hot":-1,"title":"Stock Track | Phathom Pharmaceuticals Soars 5.79% Pre-market on Strong Q3 Results and Analyst Upgrade","media":"Stock Track","content":"<p>Phathom Pharmaceuticals (PHAT) stock is surging 5.79% in pre-market trading on Friday, following the release of its third-quarter 2025 earnings report and a positive analyst update. The pharmaceutical company's shares are gaining momentum as investors react to the latest financial results and revised market outlook.</p>\n\n<p>The company's Q3 earnings release, while details are limited, suggests strong growth for Phathom Pharmaceuticals in the third quarter of 2025. This positive performance has caught the attention of Wall Street analysts, with H.C. Wainwright raising its target price for PHAT stock from $20 to $26, signaling increased confidence in the company's future prospects.</p>\n\n<p>Adding to the bullish sentiment, HC Wainwright & Co. has maintained its Buy rating on Phathom Pharmaceuticals. This combination of strong quarterly results and analyst optimism appears to be driving the significant pre-market rally, as investors position themselves ahead of the regular trading session in anticipation of potential further gains.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Phathom Pharmaceuticals Soars 5.79% Pre-market on Strong Q3 Results and Analyst Upgrade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Phathom Pharmaceuticals Soars 5.79% Pre-market on Strong Q3 Results and Analyst Upgrade\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-10-31 21:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Phathom Pharmaceuticals (PHAT) stock is surging 5.79% in pre-market trading on Friday, following the release of its third-quarter 2025 earnings report and a positive analyst update. The pharmaceutical company's shares are gaining momentum as investors react to the latest financial results and revised market outlook.</p>\n\n<p>The company's Q3 earnings release, while details are limited, suggests strong growth for Phathom Pharmaceuticals in the third quarter of 2025. This positive performance has caught the attention of Wall Street analysts, with H.C. Wainwright raising its target price for PHAT stock from $20 to $26, signaling increased confidence in the company's future prospects.</p>\n\n<p>Adding to the bullish sentiment, HC Wainwright & Co. has maintained its Buy rating on Phathom Pharmaceuticals. This combination of strong quarterly results and analyst optimism appears to be driving the significant pre-market rally, as investors position themselves ahead of the regular trading session in anticipation of potential further gains.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PHAT","symbol_name":"Phathom Pharmaceuticals","start_time":0,"source_url":"","article_id":"1159604203","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1159604203","pubTimestamp":1761917299,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Phathom Pharmaceuticals (PHAT) stock is surging 5.79% in pre-market trading on Friday, following the release of its third-quarter 2025 earnings report and a positive analyst update. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PHAT":"Phathom Pharmaceuticals"},"translate_title":"个股追踪|Phathom Pharmaceuticals盘前大涨5.79%因Q3业绩强劲及分析师上调评级","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PHAT":1},"content_text":"Phathom Pharmaceuticals (PHAT) stock is surging 5.79% in pre-market trading on Friday, following the release of its third-quarter 2025 earnings report and a positive analyst update. The pharmaceutical company's shares are gaining momentum as investors react to the latest financial results and revised market outlook.\nThe company's Q3 earnings release, while details are limited, suggests strong growth for Phathom Pharmaceuticals in the third quarter of 2025. This positive performance has caught the attention of Wall Street analysts, with H.C. Wainwright raising its target price for PHAT stock from $20 to $26, signaling increased confidence in the company's future prospects.\nAdding to the bullish sentiment, HC Wainwright & Co. has maintained its Buy rating on Phathom Pharmaceuticals. This combination of strong quarterly results and analyst optimism appears to be driving the significant pre-market rally, as investors position themselves ahead of the regular trading session in anticipation of potential further gains.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}